查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1989037

神经免疫疗法市场预测至2034年—按治疗方法类型、适应症、给药途径、技术、最终用户、分销管道和地区分類的全球分析

Neuroimmune Therapy Market Forecasts to 2034 - Global Analysis By Therapy Type, Indication, Route of Administration, Technology, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球神经免疫疗法市场规模将达到 282 亿美元，并在预测期内以 10.6% 的复合年增长率增长，到 2034 年将达到 633 亿美元。

神经免疫疗法是指透过针对神经系统和免疫系统的交叉点，来治疗由异常免疫活动引起或加剧的神经系统疾病的医疗手段。这些治疗方法包括单株抗体、自体免疫、细胞激素抑制剂、细胞疗法和基因疗法，旨在调节神经发炎并恢復免疫平衡，用于治疗多发性硬化症、自体免疫性脑炎和神经退化性疾病等疾病。透过精准调节大脑和神经系统中的免疫通路，神经免疫疗法为过去难以治疗或控制不佳的神经系统疾病患者带来了新的希望。

自体免疫神经系统疾病盛行率增加

随着人口老化和诊断能力的提高，包括多发性硬化症、视神经脊髓炎、自体免疫脑炎和神经发炎性阿兹海默症在内的神经免疫疾病的全球负担日益加重。对神经损伤免疫机制的深入了解，为靶向生技药品、免疫调节剂和细胞疗法等新的治疗方案开闢了道路。患者数量的不断增长、巨大的未满足医疗需求以及神经免疫学领域的快速发展，正推动着製药企业对相关药物的研发和商业化进行大量投资。

药物研发和临床试验成本高昂

开发新型神经免疫疗法，特别是针对中枢神经系统的生物製药（例如单株抗体和细胞疗法），需要巨额的前期投资，用于标靶检验、临床前试验、多阶段临床试验以及生产基础设施建设。由于难以客观评估疗效以及临床试验设计的复杂性，在神经系统疾病适应症中确立药物的安全性和有效性极具挑战性，这进一步增加了研发成本和时间。神经系统药物研发的高失败率带来了巨大的财务风险。

不断扩充的生物神经治疗候选药物研发管线

神经免疫疗法研发管线是整个生物製药产业中最活跃、最具创新性的领域之一，众多新型候选疗法正处于后期临床开发阶段，针对多发性硬化症、阿兹海默症相关的神经发炎以及罕见的自体免疫神经系统疾病。抗体工程、CAR-T细胞技术、反义寡核苷酸和基因治疗平台的进步正在拓展可治疗的神经免疫标靶范围。随着有前景的候选药物逐步获得监管部门的核准，这项丰富的研发管线蕴藏着巨大的商业性机会。

新型生物製药的复杂核准流程

针对中枢神经系统的新型生物製药的监管核准流程是药物研发中最严格、最难预测的流程之一。监管机构要求提供大量临床证据，证明其在神经系统疾病适应症的安全性和有效性，通常需要进行大型、长期的临床试验，并设定复杂的终点指标。此外，生产符合监管核准所需的品质和一致性标准的生物製药也需要付出更高的成本和更大的复杂性。

新冠疫情的影响：

新冠疫情对神经免疫疗法市场产生了重大影响，凸显了免疫系统与神经系统相互作用在健康结果中的关键作用。新冠感染疾病和免疫失调的研究不断深入，加速了人们对神经免疫疗法的兴趣。製药公司和研究机构投入大量资金开发针对併发症和免疫相关神经系统疾病的治疗方法。儘管监管限制导致临床试验延期，但从长远来看，其影响是积极的，人们对神经免疫疗法的认识不断提高，推动了创新，并使其成为现代医疗保健的重要组成部分。

在预测期内，单株抗体领域预计将占据最大份额。

单株抗体疗法在神经免疫治疗市场中占最大份额。这些高度特异性的生物製剂透过选择性靶向病理性免疫通路，彻底改变了多发性硬化症、视神经脊髓炎和其他自体免疫神经系统疾病的治疗。其已证实的临床疗效、成熟的生产流程以及不断增加的核准产品，造就了一个规模庞大且商业性占据主导地位的细分市场。随着临床试验不断探索新的神经免疫适应症，单株抗体疗法的潜在市场正在进一步扩大。

预计在预测期内，多发性硬化症细分市场将呈现最高的复合年增长率。

在预测期内，多发性硬化症 (MS) 细分市场预计将在神经免疫疗法市场中实现最高的复合年增长率 (CAGR)。多发性硬化症 (MS) 是全球最常见严重的神经免疫疾病，确诊患者人数不断增加，对更有效的治疗方法的需求也远未得到满足。下一代疾病修正治疗的快速发展、生物製药治疗选择的扩展以及对 MS 患者精准神经免疫学投入的增加，正在推动该细分市场在预测期内保持卓越的复合年增长率。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额，这得益于其先进的医疗保健基础设施、强大的製药公司网路以及对神经免疫学研究的大力投入。该地区受益于政府的支持、自体免疫疾病和神经系统疾病的高发生率以及生物技术公司与学术机构之间的合作。此外，创新治疗方法的早期应用和健全的法规结构确保北美继续保持神经免疫疗法开发和商业化的领先地位。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于医疗保健支出不断增长、人们对神经系统和免疫相关疾病的认识日益提高以及药物研发能力的不断增强。中国、印度和日本等国家正大力投资生技和先进治疗方法，并得到政府推动医疗创新措施的支持。神经免疫疾病盛行率的不断上升以及庞大的患者群体正在推动市场需求。科技的快速应用和扶持政策使亚太地区成为该市场成长最快的地区。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章：执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球神经免疫疗法市场：依治疗方法划分

  • 单株抗体
  • 免疫调节剂
  • 细胞激素抑制剂
  • 细胞疗法
  • 基因治疗
  • 小分子药物
  • 联合治疗

第六章：全球神经免疫疗法市场：依适应症划分

  • 多发性硬化症
  • 视神经脊髓炎
  • 自体免疫脑炎
  • 重症肌无力
  • 阿兹海默症
  • 帕金森氏症

第七章 全球神经免疫疗法市场：依给药途径划分

  • 静脉
  • 皮下
  • 口服
  • 鞘内腔

第八章 全球神经免疫疗法市场：依技术划分

  • 生物製药开发
  • 重组DNA技术
  • 细胞工程
  • 精准医疗平台

第九章 全球神经免疫疗法市场：依最终用户划分

  • 医院
  • 专科诊所
  • 研究机构
  • 门诊手术中心

第十章 全球神经免疫疗法市场：依分销管道划分

  • 医院药房
  • 零售药房
  • 网路药房

第十一章 全球神经免疫疗法市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十二章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十三章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十四章：公司简介

  • Roche Holding AG
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Biogen Inc.
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Sanofi SA
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Amgen Inc.
  • UCB SA
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca plc
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC34326

According to Stratistics MRC, the Global Neuroimmune Therapy Market is accounted for $28.2 billion in 2026 and is expected to reach $63.3 billion by 2034 growing at a CAGR of 10.6% during the forecast period. Neuroimmune therapy refers to medical treatments that target the intersection of the nervous system and immune system to address neurological diseases driven or worsened by abnormal immune activity. These therapies include monoclonal antibodies, immunomodulators, cytokine inhibitors, cell-based treatments, and gene therapies designed to regulate neuroinflammation and restore immune balance in conditions such as multiple sclerosis, autoimmune encephalitis, and neurodegenerative diseases. By precisely modulating immune pathways in the brain and nervous system, neuroimmune therapies offer new hope for patients with previously untreatable or poorly managed neurological conditions.

Market Dynamics:

Driver:

Rising prevalence of autoimmune neurological diseases

The global burden of neuroimmune diseases, including multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, and neuroinflammatory forms of Alzheimer's disease, is growing as populations age and diagnostic capabilities improve. Advances in understanding the immunological mechanisms underlying neurological damage have opened new therapeutic windows that targeted biologics, immunomodulators, and cell-based therapies can exploit. The combination of growing patient populations, significant unmet medical need, and rapidly maturing neuroimmunology science is driving substantial pharmaceutical investment in developing and commercializing.

Restraint:

High drug development and clinical trial costs

Developing novel neuroimmune therapies, particularly biologic agents such as monoclonal antibodies and cell-based therapies targeting the central nervous system, requires enormous upfront investment in target validation, preclinical studies, multi-phase clinical trials, and manufacturing infrastructure development. The complexity of demonstrating safety and efficacy in neurological indications, where outcomes are difficult to measure objectively and clinical trial designs are complex, further inflates development costs and timelines. High failure rates in neurology drug development create substantial financial risk.

Opportunity:

Growing pipeline of biologic neurotherapy candidates

The neuroimmune therapy pipeline is among the most active and innovative segments of the broader biopharmaceutical industry, with numerous novel therapeutic candidates in advanced clinical development targeting multiple sclerosis, Alzheimer's neuroinflammation, and rare autoimmune neurological disorders. Advances in antibody engineering, CAR-T cell technology, antisense oligonucleotides, and gene therapy platforms are expanding the range of neuroimmune targets that can be addressed therapeutically. This rich pipeline represents a substantial commercial opportunity as successful candidates advance toward regulatory.

Threat:

Complex regulatory approval for novel biologics

The regulatory pathway for novel biologic therapies targeting the central nervous system is among the most demanding and unpredictable in pharmaceutical development. Regulatory agencies require extensive clinical evidence of safety and efficacy in neurological indications, often including large and long-duration trials with complex outcome measures. Manufacturing biologics to quality and consistency standards required for regulatory approval adds further complexity and cost.

Covid-19 Impact:

The Covid-19 pandemic significantly influenced the Neuroimmune Therapy Market, as the virus highlighted the critical role of immune and neurological interactions in health outcomes. Increased research into post-Covid neurological complications and immune dysregulation accelerated interest in neuroimmune therapies. Pharmaceutical companies and research institutions invested heavily in developing treatments targeting inflammation and immune-related neurological disorders. While clinical trials faced delays due to restrictions, the long-term impact was positive, with heightened awareness driving innovation and positioning neuroimmune therapies as vital in modern healthcare.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment holds the largest share in the neuroimmune therapy market. These highly specific biologics have transformed treatment for multiple sclerosis, neuromyelitis optica, and other autoimmune neurological conditions by selectively targeting pathological immune pathways. Their proven clinical efficacy, established manufacturing processes, and growing number of approved products create a large and commercially dominant segment. Continued clinical trials exploring new neuroimmune indications further expand the addressable market for monoclonal antibody therapies.

The multiple sclerosis segment is expected to have the highest CAGR during the forecast period

The multiple sclerosis segment is expected to register the highest CAGR in the neuroimmune therapy market over the forecast period. MS remains the most prevalent serious neuroimmune disease globally, with a growing diagnosed patient population and strong unmet medical need for more effective therapies. Rapid development of next-generation disease-modifying therapies, expanding biological treatment options, and increasing investment in precision neuroimmune medicine for MS patients are driving the segment's exceptional compound annual growth rate across the forecast period.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure, strong presence of pharmaceutical companies, and robust investment in neuroimmune research. The region benefits from supportive government initiatives, high prevalence of autoimmune and neurological disorders, and collaborations between biotech firms and academic institutions. Additionally, early adoption of innovative therapies and strong regulatory frameworks ensure North America remains the leading hub for neuroimmune therapy development and commercialization.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rising healthcare expenditure, growing awareness of neurological and immune-related conditions, and expanding pharmaceutical research capabilities. Countries such as China, India, and Japan are investing heavily in biotechnology and advanced therapies, supported by government initiatives promoting healthcare innovation. Increasing prevalence of neuroimmune disorders, coupled with a large patient population, drives demand. With rapid technological adoption and supportive policies, Asia Pacific emerges as the fastest-growing region in this market.

Key players in the market

Some of the key players in Neuroimmune Therapy Market include Roche Holding AG, Novartis AG, Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Biogen Inc., Merck & Co., Inc., Eli Lilly and Company, Sanofi S.A., AbbVie Inc., GlaxoSmithKline plc, Amgen Inc., UCB S.A., Takeda Pharmaceutical Company Limited, AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Bayer AG, and Teva Pharmaceutical Industries Ltd.

Key Developments:

In February 2026, Pfizer emphasized AI-enabled neuroimmune therapy platforms, projecting improved treatment efficiency and patient monitoring. At global medical summits, the company showcased demand response automation for neurological care, highlighting sustainability, personalization, and resilience in addressing complex immune-related health challenges.

In January 2026, Roche advanced neuroimmune therapy research, unveiling AI-driven analytics for personalized treatment pathways. The company emphasized demand-responsive clinical solutions, integrating predictive models to optimize resilience, efficiency, and patient outcomes across neurological and autoimmune conditions worldwide.

In January 2026, Novartis introduced innovative neuroimmune therapies, leveraging digital twins and machine learning for adaptive treatment. The initiative focused on demand-responsive drug development, enhancing sustainability, efficiency, and resilience while supporting flexible deployment across hospitals, clinics, and global healthcare ecosystems.

Therapy Types Covered:

  • Monoclonal Antibodies
  • Immunomodulators
  • Cytokine Inhibitors
  • Cell-Based Therapies
  • Gene Therapies
  • Small Molecule Drugs
  • Combination Therapies

Indications Covered:

  • Multiple Sclerosis
  • Neuromyelitis Optica
  • Autoimmune Encephalitis
  • Myasthenia Gravis
  • Alzheimer's Disease
  • Parkinson's Disease

Route of Administrations Covered:

  • Intravenous
  • Subcutaneous
  • Oral
  • Intratheca

Technologies Covered:

  • Biologics Development
  • Recombinant DNA Technology
  • Cell Engineering
  • Precision Medicine Platforms

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Ambulatory Surgical Centers

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Neuroimmune Therapy Market, By Therapy Type

  • 5.1 Monoclonal Antibodies
  • 5.2 Immunomodulators
  • 5.3 Cytokine Inhibitors
  • 5.4 Cell-Based Therapies
  • 5.5 Gene Therapies
  • 5.6 Small Molecule Drugs
  • 5.7 Combination Therapies

6 Global Neuroimmune Therapy Market, By Indication

  • 6.1 Multiple Sclerosis
  • 6.2 Neuromyelitis Optica
  • 6.3 Autoimmune Encephalitis
  • 6.4 Myasthenia Gravis
  • 6.5 Alzheimer's Disease
  • 6.6 Parkinson's Disease

7 Global Neuroimmune Therapy Market, By Route of Administration

  • 7.1 Intravenous
  • 7.2 Subcutaneous
  • 7.3 Oral
  • 7.4 Intrathecal

8 Global Neuroimmune Therapy Market, By Technology

  • 8.1 Biologics Development
  • 8.2 Recombinant DNA Technology
  • 8.3 Cell Engineering
  • 8.4 Precision Medicine Platforms

9 Global Neuroimmune Therapy Market, By End User

  • 9.1 Hospitals
  • 9.2 Specialty Clinics
  • 9.3 Research Institutes
  • 9.4 Ambulatory Surgical Centers

10 Global Neuroimmune Therapy Market, By Distribution Channel

  • 10.1 Hospital Pharmacies
  • 10.2 Retail Pharmacies
  • 10.3 Online Pharmacies

11 Global Neuroimmune Therapy Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Roche Holding AG
  • 14.2 Novartis AG
  • 14.3 Pfizer Inc.
  • 14.4 Johnson & Johnson
  • 14.5 Bristol-Myers Squibb Company
  • 14.6 Biogen Inc.
  • 14.7 Merck & Co., Inc.
  • 14.8 Eli Lilly and Company
  • 14.9 Sanofi S.A.
  • 14.10 AbbVie Inc.
  • 14.11 GlaxoSmithKline plc
  • 14.12 Amgen Inc.
  • 14.13 UCB S.A.
  • 14.14 Takeda Pharmaceutical Company Limited
  • 14.15 AstraZeneca plc
  • 14.16 Regeneron Pharmaceuticals, Inc.
  • 14.17 Bayer AG
  • 14.18 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Neuroimmune Therapy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Neuroimmune Therapy Market Outlook, By Therapy Type (2023-2034) ($MN)
  • Table 3 Global Neuroimmune Therapy Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 4 Global Neuroimmune Therapy Market Outlook, By Immunomodulators (2023-2034) ($MN)
  • Table 5 Global Neuroimmune Therapy Market Outlook, By Cytokine Inhibitors (2023-2034) ($MN)
  • Table 6 Global Neuroimmune Therapy Market Outlook, By Cell-Based Therapies (2023-2034) ($MN)
  • Table 7 Global Neuroimmune Therapy Market Outlook, By Gene Therapies (2023-2034) ($MN)
  • Table 8 Global Neuroimmune Therapy Market Outlook, By Small Molecule Drugs (2023-2034) ($MN)
  • Table 9 Global Neuroimmune Therapy Market Outlook, By Combination Therapies (2023-2034) ($MN)
  • Table 10 Global Neuroimmune Therapy Market Outlook, By Indication (2023-2034) ($MN)
  • Table 11 Global Neuroimmune Therapy Market Outlook, By Multiple Sclerosis (2023-2034) ($MN)
  • Table 12 Global Neuroimmune Therapy Market Outlook, By Neuromyelitis Optica (2023-2034) ($MN)
  • Table 13 Global Neuroimmune Therapy Market Outlook, By Autoimmune Encephalitis (2023-2034) ($MN)
  • Table 14 Global Neuroimmune Therapy Market Outlook, By Myasthenia Gravis (2023-2034) ($MN)
  • Table 15 Global Neuroimmune Therapy Market Outlook, By Alzheimer's Disease (2023-2034) ($MN)
  • Table 16 Global Neuroimmune Therapy Market Outlook, By Parkinson's Disease (2023-2034) ($MN)
  • Table 17 Global Neuroimmune Therapy Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 18 Global Neuroimmune Therapy Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 19 Global Neuroimmune Therapy Market Outlook, By Subcutaneous (2023-2034) ($MN)
  • Table 20 Global Neuroimmune Therapy Market Outlook, By Oral (2023-2034) ($MN)
  • Table 21 Global Neuroimmune Therapy Market Outlook, By Intrathecal (2023-2034) ($MN)
  • Table 22 Global Neuroimmune Therapy Market Outlook, By Technology (2023-2034) ($MN)
  • Table 23 Global Neuroimmune Therapy Market Outlook, By Biologics Development (2023-2034) ($MN)
  • Table 24 Global Neuroimmune Therapy Market Outlook, By Recombinant DNA Technology (2023-2034) ($MN)
  • Table 25 Global Neuroimmune Therapy Market Outlook, By Cell Engineering (2023-2034) ($MN)
  • Table 26 Global Neuroimmune Therapy Market Outlook, By Precision Medicine Platforms (2023-2034) ($MN)
  • Table 27 Global Neuroimmune Therapy Market Outlook, By End User (2023-2034) ($MN)
  • Table 28 Global Neuroimmune Therapy Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 29 Global Neuroimmune Therapy Market Outlook, By Specialty Clinics (2023-2034) ($MN)
  • Table 30 Global Neuroimmune Therapy Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 31 Global Neuroimmune Therapy Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
  • Table 32 Global Neuroimmune Therapy Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 33 Global Neuroimmune Therapy Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 34 Global Neuroimmune Therapy Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 35 Global Neuroimmune Therapy Market Outlook, By Online Pharmacies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.